Repligen Corporation (NASDAQ:RGEN) Stock Has Consensus Target Price of $175.71 According to Analysts

Repligen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately bullish: Eighteen firms give Repligen a consensus “Moderate Buy” rating, with 12 buys, two strong buys and four holds. The average 12-month price target is $175.71.
  • Recent ratings were mixed but generally supportive, including Citigroup’s upgrade to “buy” and Barclays’ price-target increase to $225 with an “overweight” rating; Evercore maintained an “outperform” rating with a $160 target.
  • Repligen exceeded quarterly expectations, reporting $0.54 in EPS versus $0.45 expected and revenue of $204.13 million, up 11.9% year over year. Institutional investors own 97.64% of the stock, which opened at $176.93 and carries a market capitalization of about $9.99 billion.
  • Interested in Repligen? Here are five stocks we like better.

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) have earned an average rating of "Moderate Buy" from the eighteen ratings firms that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $175.71.

A number of brokerages recently commented on RGEN. Evercore reaffirmed an "outperform" rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. Weiss Ratings raised Repligen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Citigroup upgraded Repligen to a "buy" rating in a research report on Tuesday, July 7th. Zacks Research downgraded Repligen from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th. Finally, Barclays raised their price objective on Repligen from $175.00 to $225.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th.

Check Out Our Latest Report on RGEN

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Evergreen Capital Management LLC bought a new stake in Repligen in the third quarter worth $217,000. Gibbs Wealth Management boosted its stake in Repligen by 7.7% during the third quarter. Gibbs Wealth Management now owns 12,866 shares of the biotechnology company's stock worth $2,473,000 after buying an additional 917 shares during the period. Yousif Capital Management LLC increased its position in Repligen by 1.3% during the third quarter. Yousif Capital Management LLC now owns 12,604 shares of the biotechnology company's stock valued at $2,423,000 after acquiring an additional 160 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in Repligen by 3.5% during the third quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company's stock valued at $870,000 after acquiring an additional 152 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its position in Repligen by 7.7% during the third quarter. Diversify Advisory Services LLC now owns 20,028 shares of the biotechnology company's stock valued at $3,689,000 after acquiring an additional 1,434 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Price Performance

RGEN stock opened at $176.93 on Friday. Repligen has a 52 week low of $100.99 and a 52 week high of $198.87. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The company has a fifty day simple moving average of $177.12 and a two-hundred day simple moving average of $147.67. The firm has a market capitalization of $9.99 billion, a P/E ratio of 242.37, a price-to-earnings-growth ratio of 3.26 and a beta of 1.08.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million during the quarter, compared to analysts' expectations of $201.59 million. During the same period last year, the company posted $0.26 EPS. The business's revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts anticipate that Repligen will post 2.06 earnings per share for the current fiscal year.

About Repligen

(Get Free Report)

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

Featured Articles

Analyst Recommendations for Repligen (NASDAQ:RGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines